Saturday 17 October 2026
Export CAPS’s income statement to Excel — free account
Capstone Therapeutics Corp.
CAPS Basic Materials Building Materials
Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024. In the quarter to June 2026, revenue grew 67.1%, EPS grew 15.4%, free cash flow grew 73.4% and total debt rose 45.9%, each against the same quarter a year earlier.
0.09
0.01
−10.00%
Follow CAPS
| Dec '25 | Dec '24 | Dec '23 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
(5.67) | (4.90) | (4.19) | (179.60) | — | — |
P/S ratio |
0.08 | 0.01 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(14.93) | (13.66) | (11.76) | (419.24) | — | — |
P/FCF ratio |
0.00 | 0.09 | 0.00 | 16.48 | — | — |
Beneish M-Score |
(3.81) | (3.01) | — | — | — | — |
P/Operating CF |
(9.25) | 0.13 | (0.36) | (2.29) | — | — |
P/B ratio |
0.31 | 0.00 | 0.00 | 0.00 | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Sales |
0.57 | 0.33 | 0.00 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(6.01) | 3.82 | (1.29) | 33.67 | — | — |
EV/FCF |
(5.85) | 3.94 | (1.29) | 33.67 | — | — |
Quick Ratio |
0.24 | 0.22 | 0.16 | 5.45 | 6.41 | 2.30 |
Current Ratio |
1.00 | 1.02 | 1.07 | 5.85 | 6.90 | 2.73 |
Net Debt/EBITDA |
(2.69) | (43.98) | (21.70) | (47.25) | (0.66) | (0.21) |
Debt/Assets |
45.47% | 30.57% | 32.83% | 167.57% | 143.34% | 84.60% |
Debt/Equity |
1.88 | (4.72) | 7.10 | (1.99) | (2.56) | (8.20) |
Asset Turnover |
0.95 | 0.90 | 1.79 | 1.31 | 0.00 | 0.00 |
Operating CF/Net income |
0.20 | (0.70) | (0.29) | (0.17) | 0.89 | 1.90 |
Capex/Depreciation |
(0.06) | (0.60) | (0.45) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(2.83) | (0.43) | (0.75) | — | — | — |
| (468.45%) | 1,769.73% | (961.44%) | 35.80% | 350.65% | (345.31%) | |
| (44.49%) | (11.00%) | (21.17%) | (24.95%) | (127.59%) | (44.96%) | |
ROIC |
(19.57%) | (3.51%) | (3.99%) | 0.00% | (1,105.26%) | (550.00%) |
Return on Tangible Assets |
(1,014.10%) | (297.99%) | (200.10%) | (31.88%) | (149.49%) | (126.29%) |
Average Days of Receivables |
37.87 | 22.46 | 19.48 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 68.65% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
30.66% | 22.75% | 22.47% | 27.70% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.40 | 0.49 | 0.44 | 0.03 | 0.12 | 0.30 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.75% | — | 0.00% |
Graham Net Nets |
(4.10) | (106.13) | (9.76) | (1.18) | — | — |
Graham Number |
0.00 | 84.26 | 0.00 | 70.62 | — | — |
Earnings Yield |
(497.26%) | (725.97%) | (873.35%) | (48.46%) | — | — |
Free Cash Flow Yield |
(116.71%) | 1,061.68% | (719.74%) | 6.07% | — | — |
Revenue per Share |
8.81 | 284.75 | 306.81 | 36.76 | 0.00 | 0.00 |
Operating CF per Share |
(0.83) | 24.54 | 10.47 | 1.21 | (33.07) | (30.78) |
Capex per Share |
(0.03) | (1.18) | (1.32) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.86) | 23.36 | 9.15 | 1.21 | (33.07) | (30.78) |
Cash per Share |
0.14 | 0.07 | 0.33 | 24.65 | 27.01 | 17.07 |
Shareholders Equity per Share |
2.34 | (19.40) | 15.46 | (22.87) | (18.62) | (2.98) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.34 | (19.40) | 15.46 | (22.87) | (18.62) | (2.98) |
Free Cash Flow |
(4.57) | 3.68 | 1.44 | 0.07 | (1.56) | (1.26) |
Working Capital |
0.08 | 0.25 | 1.11 | 1.19 | 1.17 | 0.53 |
Capital Expenditures |
(0.16) | (0.19) | (0.21) | — | — | — |
Net Current Asset Value |
(15.92) | (37.47) | (33.18) | (1.28) | (1.07) | (0.47) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
1.23 | 0.19 | 0.26 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(12.51%) | 32.33% | 7.29% | 2.57% | (59.02%) | (79.89%) |
Accounts Receivable Turnover |
12.30 | 16.80 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
8.74 | 12.01 | 27.48 | 1.15 | 0.00 | 0.00 |
Inventory Turnover |
2.70 | 3.02 | 0.00 | 0.00 | — | — |
Average Days of Payables |
50.14 | 34.16 | 24.26 | 352.07 | 0.00 | 0.00 |
Days of Inventory on Hand |
172.56 | 99.61 | 129.54 | 0.00 | — | — |
Average Receivables |
3.81 | 2.67 | — | — | — | — |
Average Payables |
4.13 | 2.94 | 1.41 | 0.22 | 0.22 | 0.25 |
Average Inventory |
13.35 | 11.69 | — | — | — | — |
Average Assets |
49.30 | 49.96 | 27.09 | 1.52 | 1.38 | 1.47 |
Average Common Equity |
4.68 | (0.31) | 0.60 | (1.06) | (0.50) | 0.19 |
Columns are period end dates